Quick Answer
Moderna, Inc. reported Total Assets of $12.34 billion for the year ending 2025.
- Moderna, Inc. showed a decrease of -12.8% in Total Assets from 2024 to 2025.
- This data is from Moderna, Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $1.81 billion | Q2 2019: $1.69 billion | Q3 2019: $1.59 billion | Q1 2020: $2.07 billion | Q2 2020: $3.49 billion | Q3 2020: $4.65 billion | Q1 2021: $12.69 billion | Q2 2021: $16.15 billion | Q3 2021: $20.92 billion | Q1 2022: $27.61 billion | Q2 2022: $26.04 billion | Q3 2022: $26.06 billion | Q1 2023: $24.13 billion | Q2 2023: $21.88 billion | Q3 2023: $19.45 billion | Q1 2024: $16.73 billion | Q2 2024: $15.68 billion | Q3 2024: $15.80 billion | Q1 2025: $12.70 billion | Q2 2025: $12.01 billion | Q3 2025: $12.14 billion.
- Over the full 9 years of available data (2017 to 2025), Moderna, Inc.'s Total Assets has grown by 1,037.7%.
- Historical annual values: Fiscal year 2025: $12.34 billion | Fiscal year 2024: $14.14 billion | Fiscal year 2023: $18.43 billion | Fiscal year 2022: $25.86 billion | Fiscal year 2021: $24.67 billion | Fiscal year 2020: $7.34 billion | Fiscal year 2019: $1.59 billion | Fiscal year 2018: $1.96 billion | Fiscal year 2017: $1.08 billion.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: